Attached files
| file | filename |
|---|---|
| EX-10.3 - EX-10.3 - C4 Therapeutics, Inc. | d772024dex103.htm |
| EX-10.2 - EX-10.2 - C4 Therapeutics, Inc. | d772024dex102.htm |
| EX-5.1 - EX-5.1 - C4 Therapeutics, Inc. | d772024dex51.htm |
| EX-4.3 - EX-4.3 - C4 Therapeutics, Inc. | d772024dex43.htm |
| EX-3.2 - EX-3.2 - C4 Therapeutics, Inc. | d772024dex32.htm |
| EX-1.1 - EX-1.1 - C4 Therapeutics, Inc. | d772024dex11.htm |
| S-1/A - S-1/A - C4 Therapeutics, Inc. | d772024ds1a.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
C4 Therapeutics, Inc.:
We consent to the use of our report dated August 5, 2020, except as to Note 13, which is as of September 28, 2020, included herein and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Boston, Massachusetts
September 28, 2020